Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Drug Saf. 2022 May;45(5):477-491. doi: 10.1007/s40264-022-01176-1. Epub 2022 May 17.
Artificial intelligence based on machine learning has made large advancements in many fields of science and medicine but its impact on pharmacovigilance is yet unclear.
The present study conducted a scoping review of the use of artificial intelligence based on machine learning to understand how it is used for pharmacovigilance tasks, characterize differences with other fields, and identify opportunities to improve pharmacovigilance through the use of machine learning.
The PubMed, Embase, Web of Science, and IEEE Xplore databases were searched to identify articles pertaining to the use of machine learning in pharmacovigilance published from the year 2000 to September 2021. After manual screening of 7744 abstracts, a total of 393 papers met the inclusion criteria for further analysis. Extraction of key data on study design, data sources, sample size, and machine learning methodology was performed. Studies with the characteristics of good machine learning practice were defined and manual review focused on identifying studies that fulfilled these criteria and results that showed promise.
The majority of studies (53%) were focused on detecting safety signals using traditional statistical methods. Of the studies that used more recent machine learning methods, 61% used off-the-shelf techniques with minor modifications. Temporal analysis revealed that newer methods such as deep learning have shown increased use in recent years. We found only 42 studies (10%) that reflect current best practices and trends in machine learning. In the subset of 154 papers that focused on data intake and ingestion, 30 (19%) were found to incorporate the same best practices.
Advances from artificial intelligence have yet to fully penetrate pharmacovigilance, although recent studies show signs that this may be changing.
基于机器学习的人工智能在许多科学和医学领域取得了重大进展,但它对药物警戒的影响尚不清楚。
本研究对基于机器学习的人工智能在药物警戒中的应用进行了范围界定综述,以了解其在药物警戒任务中的应用方式、与其他领域的差异,并确定通过使用机器学习改进药物警戒的机会。
检索了 PubMed、Embase、Web of Science 和 IEEE Xplore 数据库,以确定 2000 年至 2021 年 9 月期间发表的关于机器学习在药物警戒中应用的文章。在手动筛选了 7744 篇摘要后,共有 393 篇论文符合进一步分析的纳入标准。提取了关于研究设计、数据来源、样本量和机器学习方法的关键数据。定义了具有良好机器学习实践特征的研究,并进行了手动审查,重点是识别符合这些标准的研究和显示出前景的结果。
大多数研究(53%)侧重于使用传统统计方法检测安全信号。在使用较新的机器学习方法的研究中,61%的研究使用了经过少量修改的现成技术。时间分析表明,深度学习等较新方法近年来的使用有所增加。我们仅发现 42 项研究(10%)反映了当前机器学习的最佳实践和趋势。在专注于数据输入和摄取的 154 篇论文中,有 30 篇(19%)被发现采用了相同的最佳实践。
虽然最近的研究表明这种情况可能正在改变,但人工智能的进步尚未完全渗透到药物警戒中。